Drug Profile
RG 3039
Alternative Names: PF 6687859; PF-06687859; Quinazoline 495; RG3039Latest Information Update: 26 Apr 2016
Price :
$50
*
At a glance
- Originator Families of SMA
- Developer Repligen Corporation
- Class Small molecules
- Mechanism of Action DcpS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Spinal muscular atrophy